http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2695182-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1ef6f1a6319f01bb92d09c61a4f0e76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 |
| filingDate | 2014-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d075e042832d971eb1dc7515bd684a9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e03ecfc0d09fc05169accab2f5094802 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74515693e96ae6aaa2fd9790ca4b2d06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb9ca0a86ca93b91c62decc74e8339ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b25bfe61895c756bbfd0b758b741b090 |
| publicationDate | 2019-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2695182-T3 |
| titleOfInvention | Derivatives of sulfamoyl thiophenamide and its use as medicines to treat hepatitis B |
| abstract | A compound of formula (I) ** Formula ** or a stereoisomer or tautomeric form thereof, where: One X is S and the other two X represent CR4; R2 is fluoro or hydrogen; R1 and R3 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, CHF2, CH2F, CF3, CN and methyl, where at least one of R1 and R3 is not hydrogen and R1 and R3 are not ortho methyl or ortho chlorine; One R4 is hydrogen and the other R4 is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, cyclopropyl, CHF2, CH2F and CF3; R5 is hydrogen; R6 is selected from the group consisting of C1-C6 alkyl, C1-C3-R7 alkyl and a saturated ring of 3 to 7 members optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N , wherein said 3 to 7-membered saturated ring or C1-C6 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, fluoro, OH, CF3 and C1-C4 alkyl; R7 is a saturated ring of 3 to 7 members that optionally contains one or more heteroatoms each independently selected from the group consisting of O, S and N, or C (= O) -R8; R8 is selected from the group consisting of C1-C3 alkoxy and -NH2; where if R1 is methyl, R2 is fluoro, and R3 is hydrogen, R6 is not methyl; or a pharmaceutically acceptable salt or solvate thereof. |
| priorityDate | 2013-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.